Business briefs: Quintiles and Forest, plus Paula Watch

Share this article:

Quintiles has purchased CRO Novella Clinical. The deal will bring Novella's oncology, medical device and diagnostic trials into the Quintiles portfolio, but Novella will operate as a stand-alone unit.

Forest and Almirall are delaying an experimental COPD drug submission to the FDA. The drug is a combination of two bronchodilators, and the companies said in a statement Thursday that in pre-NDA discussions with the FDA, that the regulator had questions about “resolving chemistry, manufacturing and control specifications.” The two-for-one drug combines aclidinum bromide, known by the brand name Tudorza, and formoterol fumarate.

Paula Watch: Paula Deen's rebound may have begun. One day after a judge threw out racism claims against the former Food Network star, Savannahnow.com reports that the celebrity chef may have a cameo on her son's show "Home for Dinner with Jamie Deen." Savannahnow.com notes that it is unclear if the episode was filmed before Deen's reputation began to plummet.
Share this article:
You must be a registered member of MMM to post a comment.

Reimagining healthcare? We want to hear about it.
 
Submit nominations here for MM&M's first-ever list of the Top 40 Healthcare Transformers

Email Newsletters

MM&M inVISION

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.